Naveen Baid

Thank you. Thank you for the opportunity. Sir, you spoke of three late -stage Onco and CNS candidates. Where are we in terms of the visibility on when they could be commercialized?

For all three of them?

And just some color on what would be the opportunity size for those 3 molecules? Irrespective of the timeline, whether it is ‘27 or ‘28?